Afleveringen
-
In this episode, we discuss the comeback of belantamab mafadotin in multiple myeloma with Dr. Hang Quach, along with some other important abstracts presented at EHA/ASCO 2024. Here are the studies we discussed:
1. DREAMM-7 RCT: Belantamab-Vd vs Daratumumab-Vd in relapsed MM. https://pubmed.ncbi.nlm.nih.gov/38828933/
2. DREAMM-8 RCT: Belantamab-Pd vs PVd in relapsed MM. https://pubmed.ncbi.nlm.nih.gov/38828951/
3. Long-term follow-up of CASSIOPEIA Trial: https://pubmed.ncbi.nlm.nih.gov/38889735/
4. Update on MRD data from PERSEUS Trial: https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.7502
-
In this episode, we dive into the management of older adults with Hodgkin Lymphoma with Dr. Andrew Evens.
Here are the key articles we discussed:1. Comparison of ABVD versus Stanford V in older Hodgkin Lymphoma patients: https://pmc.ncbi.nlm.nih.gov/articles/PMC3906856/
2. Outcome of older adults ECHELON-1: https://pubmed.ncbi.nlm.nih.gov/34162178/
3. Sequential BV-AVD in older adults with Hodgkin Lymphoma: https://pubmed.ncbi.nlm.nih.gov/30179569/
4. SWOG S1826 trial (Nivo-AVD vs AAVD in advanced stage classical HL): https://pubmed.ncbi.nlm.nih.gov/39413375/
5. S1826 outcomes in older adults: https://ash.confex.com/ash/2023/webprogram/Paper180114.html
6. Single-agent BV for older adults with Hodgkin: https://ashpublications.org/blood/article/142/Supplement%201/4435/503453
-
Zijn er afleveringen die ontbreken?
-
In this episode, we discuss the history of venetoclax in AML, along with key clinical trials that have shaped its current use in AML. Here are the trials discussed in this episode:
1. VIALE-A study: https://www.nejm.org/doi/full/10.1056/NEJMoa2012971
2. 10 day Decitabine plus venetoclax for ND AML https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(20)30210-6/abstract
3. Genetic Risk Stratification and Outcomes with AML treated with venetoclax and azacitidine https://ashpublications-org.proxy.library.vanderbilt.edu/blood/article/doi/10.1182/blood.2024024944/517355/Genetic-Risk-Stratification-and-Outcomes-Among
4. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations https://ashpublications-org.proxy.library.vanderbilt.edu/blood/article/doi/10.1182/blood.2024025409/517356/Genetic-risk-classification-for-adults-with-AML
5. AGILE study: Ivosidenib and azacitidine in IDH1-mutated AML https://www.nejm.org/doi/full/10.1056/NEJMoa2117344
6. MRD response and prognosis in treatment naïve AML with AZA/VEN https://ascopubs.org/doi/10.1200/JCO.21.01546?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
7. Monocytic subclone confer resistance to venetoclax-based therapy in patients with AML https://aacrjournals.org/cancerdiscovery/article/10/4/536/2403/Monocytic-Subclones-Confer-Resistance-to
8. VEN/DEC vs 7+3 https://ashpublications.org/blood/article/142/Supplement%201/970/503790/Comparing-the-Efficacy-and-Safety-of-Venetoclax
9. FILO study: Outcomes of AML https://onlinelibrary.wiley.com/doi/10.1002/ajh.27417
10. Treatment-free remission after ceasing venetoclax-based therapy in patients with AML https://ashpublications-org.proxy.library.vanderbilt.edu/bloodadvances/article/6/13/3879/485175/Treatment-free-remission-after-ceasing-venetoclax
11. Targeting molecular MRD and low-blast relapse in AML with Venetoclax and LDAC (VALDAC) https://ascopubs-org.proxy.library.vanderbilt.edu/doi/10.1200/JCO.23.01599?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
12. INTERCEPT trial: https://ashpublications.org/blood/article/140/Supplement%201/3341/492722/ALLG-AMLM26-Phase-1B-2-Study-Investigating-Novel
-
In this episode, we discuss the management of newly diagnosed transplant in-eligible multiple myeloma with Dr. Timothy Schmidt, with a special focus on IMROZ and BENEFIT RCTs testing quadruplets in this space.
Here are the key papers we discussed:
1. MAIA trial (Daratumumab-Lenalidomide-Dexamethasone [DRd] vs Rd in newly diagnosed transplant ineligible myeloma): https://pubmed.ncbi.nlm.nih.gov/34655533/
2. S0777 trial (VRd vs Rd in newly diagnosed myeloma [transplant-ineligible or transplant-deferred]): https://pubmed.ncbi.nlm.nih.gov/32393732/
3. IMROZ trial (Isatuximab-VRd vs VRd in newly diagnosed transplant-ineligible myeloma): https://pubmed.ncbi.nlm.nih.gov/38832972/
4. IFM-2020/BENEFIT trial (Isatuximab-VRd vs Isatuximab-Rd in newly diagnosed transplant-ineligible myeloma): https://pubmed.ncbi.nlm.nih.gov/38830994/
5. GEM2017FIT trial (VMP-Rd vs KRd vs Dara-KRd in newly diagnosed transplant-ineligible myeloma): https://ashpublications.org/blood/article/142/Supplement%201/209/500199
-
In this episode, we discuss updates on low-risk MDS with Dr. Maximilian Stahl with a focus on imetelstat and luspatercept.
Here are the trials we discussed:
1. IWG 2019 response criteriahttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042664/
2. MEDALIST trial: Luspatercept
https://www.nejm.org/doi/10.1056/NEJMoa1908892?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
3. COMMANDS trial : Luspatercept
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00874-7/abstract
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00203-5/abstract
4. IMerge trial: Imetelstat
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01724-5/abstract
-
In this episode, we discussed the diagnosis and management of polycythemia vera with Dr. Aaron T. Gerds. Here are the shownotes with the key studies discussed:
1. MIPS PV scoring system
https://pubmed.ncbi.nlm.nih.gov/31945802/
2. REVEAL study
https://ashpublications.org/blood/article/143/16/1646/506717/Association-between-elevated-white-blood-cell
3. MAJIC PV study
https://ascopubs.org/doi/10.1200/JCO.22.01935?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
4. Cyto-PV Study
https://www.nejm.org/doi/full/10.1056/NEJMoa1208500
5. PROUD-PV and CONTINUATION-PV trials
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(19)30236-4/abstract
6. RESPONSE clinical trial
https://www.nejm.org/doi/full/10.1056/NEJMoa1409002
7. Rusferitide in PV
https://www.nejm.org/doi/10.1056/NEJMoa2308809?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
-
In this episode, we reviewed the hottest updates in lymphoma from ASCO and EHA 2024, held in Chicago and Madrid respectively, with Dr. Gloria Iacoboni, a haematologist from University Hospital Vall d'Hebron, in Barcelona, Spain. Here are the key abstracts we discussed:
1. STARGLO: Glofit-GEMOX vs R-GEMOX in relapsed/refractory DLBCL
https://library.ehaweb.org/eha/2024/eha2024-congress/4136516
2. Epco-Pola-R-CHP for 1st line DLBCL (EPCORE NHL-5 study):
https://library.ehaweb.org/eha/2024/eha2024-congress/422343
3. 3-year follow-up of TRANSFORM (Liso-Cel vs CITàASCT in R/R DLBCL): https://meetings.asco.org/abstracts-presentations/232740
4. ECHO RCT: Acalabrutinib-BR vs Placebo-BR in previously untreated elderly MCL: https://library.ehaweb.org/eha/2024/eha2024-congress/4136515
5. HD21: escBEACOPP vs BrECADD in 1st line classical HL: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01315-1/fulltext
6. Combination pirtobrutinib, venetoclax, and obinutuzumab in 1st line CLL: https://library.ehaweb.org/eha/2024/eha2024-congress/422268
7. Single-agent epcoritamab in Richter’s transformation: EPCORE CLL-1: https://library.ehaweb.org/eha/2024/eha2024-congress/422267
-
In this episode, we dive into updates in Minimal Residual Disease (MRD) in multiple myeloma, along with the FDA ODAC meeting in April 2024 to decide on MRD as a surrogate endpoint for accelerated approval. Our guests are Dr. Benjamin Derman and Dr. Manni Mohyuddin. Here are the key papers we discussed:
1. Recording of FDA ODAC meeting: https://www.youtube.com/watch?v=pooME9gMaL0
2. EVIDENCE meta-analysis on individual-level and trial-level correlation between MRD and PFS/OS in multiple myeloma: https://pubmed.ncbi.nlm.nih.gov/38768337/
3. Predictors of un-sustained MRD-negativity in multiple myeloma:
a) Secondary analysis of FORTE trial: https://pubmed.ncbi.nlm.nih.gov/38048557/
b) Secondary analysis of GEM2012MENOS65 and GEM2014MAIN trials: https://pubmed.ncbi.nlm.nih.gov/38048552/
4. Kinetics of MRD resurgence and subsequent relapse in multiple myeloma: https://pubmed.ncbi.nlm.nih.gov/34807986/
5. MRD2STOP trial (MRD-guided maintenance discontinuation): https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.106
6. MRD-guided maintenance discontinuation in myeloma (Secondary analysis of GEM2012MENOS65 trial): https://pubmed.ncbi.nlm.nih.gov/37506339/
-
In this episode, we discuss updates in primary myelofibrosis with Dr. Ayalew Tefferi from the Mayo Clinic.
The key studies and trials discussed are as follows:· GIPSS: Genetically inspired prognostic scoring system that is exclusively based on genetic markers.
§ https://www.nature.com/articles/s41375-018-0107-z
· MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis
§ https://ascopubs.org/doi/10.1200/JCO.2018.78.9867?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
· TRANSFORM-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis
§ https://ashpublications.org/blood/article/142/Supplement%201/620/502738/Transform-1-A-Randomized-Double-Blind-Placebo
· MANIFEST-2: Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study
§ https://ashpublications.org/blood/article/142/Supplement%201/628/502728/Pelabresib-in-Combination-with-Ruxolitinib-for
· XPORT-MF-034: Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Patients with Myelofibrosis: Long Term Follow up from XPORT-MF-034 Suggestive of Disease Modification
-
In this episode, we dive into the data on maintenance therapy in multiple myeloma with Dr. Hira Mian and Dr. Manni Mohyuddin. Here are the key studies we discussed:
1. Meta-analysis of individual patient-level data from CALGB, IFM, and Italian maintenance RCTs (lenalidomide vs placebo or observation):
https://pubmed.ncbi.nlm.nih.gov/28742454/
2. Myeloma XI RCT (lenalidomide vs observation): https://pubmed.ncbi.nlm.nih.gov/30559051/
3. Outcomes of lenalidomide maintenance stratified by cytogenetic subgroups (Secondary analysis of Myeloma XI): https://pubmed.ncbi.nlm.nih.gov/36564045/
4. Canadian real-world data on lenalidomide maintenance: https://pubmed.ncbi.nlm.nih.gov/33054120/
5. FORTE trial (Carfilzomib-Lenalidomide vs Lenalidomide): https://pubmed.ncbi.nlm.nih.gov/34774221/
6. ATLAS trial (Carfilzomib-Lenalidomide-Dexamethasone vs Lenalidomide): https://pubmed.ncbi.nlm.nih.gov/36642080/
7. Differential censoring and potential impact on PFS in ATLAS trial: https://pubmed.ncbi.nlm.nih.gov/37433885/
8. GEM2014 (Ixazomib-Lenalidomide-Dexamethasone vs Lenalidomide-Dexamethasone): https://ashpublications.org/blood/article-abstract/142/18/1518/497188
9. MASTER trial (MRD-guided treatment de-escalation): https://pubmed.ncbi.nlm.nih.gov/37776872/
10. Outcomes after MRD-guided treatment discontinuation (Secondary analysis of GEM2014MAIN trial): https://pubmed.ncbi.nlm.nih.gov/37506339/
-
In this episode, we discuss the diagnosis and management of Essential Thrombocythemia with Dr. Raajit Rampal. Here are the shownotes:
1. IPSET (revised) system, risk categories are defined by the presence of a prior thrombosis, age, and JAK2 mutation status:· Very low risk: No prior thrombosis, age ≤60 years, JAK2-unmutated
· Low risk: No prior thrombosis, age ≤60 years, JAK2-mutated
· Intermediate risk: No thrombosis, age >60 years, JAK2-unmutated
· High risk: History of thrombosis (any age/genotype), or age >60 years with JAK2 mutation
https://ashpublications.org/blood/article/120/26/5128/30914/Development-and-validation-of-an-International
2. The MIPSS-ET provides points for:
· Age > 60 years (3 points)
· Adverse mutation (SF3B1/SRSF2/U2AF1/TP53) (2 points)
· Male sex (1 point)
· White blood cell count ≥11 × 10^9/L (1 point)
· https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.16380?sid=nlm%3Apubmed
3. Aspirin
o Is there a benefit of twice-daily aspirin dosing, especially in high-risk or JAK2-mutant disease?
https://ashpublications.org/blood/article/136/2/171/454293/A-randomized-double-blind-trial-of-3-aspirin
4. Cytoreduction in High-risk ET
Hydroxyurea: https://www.nejm.org/doi/full/10.1056/NEJM199504273321704
Pegylated interferon alfa
MPD-RC 112 Mascarenhas J et al. A randomized phase 3 trial of interferon- α vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood . 2022)
https://ashpublications.org/blood/article/139/19/2931/483404/A-randomized-phase-3-trial-of-interferon-vs
Anagrelide in ET
https://ashpublications.org/blood/article/121/10/1720/31186/Anagrelide-compared-with-hydroxyurea-in-WHO
5. Ruxolitinib
In a randomized study phase 2 study (MAJIC-ET), ruxolitinib treatment did not deliver better rates of hematological response than best-available therapy, although symptoms did improve.
· MAJIC-ET study which is a randomized phase 2 trial
· ET patients resistant/intolerant to HU were randomized to receive RUX or standard treatment (HU 71%, anagrelide 48%, IFN 40%). The primary study outcome was CR, defined by normal platelet and white cell counts and normal spleen size.
· At 1 year, response was achieved in 46% of patients in the RUX group and in 44% in the standard arm, without statistically significant difference between the two groups.
· In addition, no difference was observed in the rates of thrombosis, hemorrhage, and disease transformation after 2 years of follow-up.
· MRs were also uncommon. RUX was superior, however, in symptom control.
https://ashpublications.org/blood/article/130/17/1889/36509/Ruxolitinib-vs-best-available-therapy-for-ET
-
In this episode, we talked about overall survival data from CARTITUDE-4 and KarMMa-3 that was presented at FDA ODAC meeting with Dr. Samer Al Hadidi from University of Arkansas Myeloma Center.
RCTs of BCMA CAR T-cell Therapy in Early Relapsed Multiple Myeloma:
a) KarMMa-3 (ide-cel): https://pubmed.ncbi.nlm.nih.gov/36762851/
b) CARTITUDE-4 (cilta-cel): https://pubmed.ncbi.nlm.nih.gov/37272512/
FDA ODAC on overall survival data from KarMMa-3 and CARTITUDE-4:
https://www.youtube.com/watch?v=VSjdGeeXb40 -
In this episode we discuss the management of newly diagnosed AL amyloidosis with Dr. Angela Dispenzieri from the Mayo Clinic.
Here are the key articles discussed:
1. Optimal use of tissue biopsy in AL amyloidosis: https://pubmed.ncbi.nlm.nih.gov/28271734/
2. Mayo 2004 staging: https://pubmed.ncbi.nlm.nih.gov/15365071/
3. Mayo 2012 staging: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3675680/
4. Renal staging: https://pubmed.ncbi.nlm.nih.gov/25115890/
5. Hematologic and cardiac response criteria in AL amyloidosis: https://pubmed.ncbi.nlm.nih.gov/23091105/
6. ANDROMEDA Trial: Dara-VCD vs VCD in newly diagnosed AL amyloidosis: https://pubmed.ncbi.nlm.nih.gov/34192431/
7. How I Treat AL Amyloidosis: https://pubmed.ncbi.nlm.nih.gov/34517412/
8. Venetoclax in AL amyloidosis (largest retrospective study till date):
https://pubmed.ncbi.nlm.nih.gov/33431806/
-
In this episode, we discuss top abstracts in the myeloid space from the American Society of Hematology 2023 meeting with Dr. Anand Patel.
Here are the abstracts that were discussed:1. TRANSFORM-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis
https://ash.confex.com/ash/2023/webprogram/Paper173509.html
2. MANIFEST-2: Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study
https://ash.confex.com/ash/2023/webprogram/Paper179141.html
3. Venetoclax + Decitabine vs 7+3 in AML
https://ashpublications.org/blood/article/142/Supplement%201/970/503790/Comparing-the-Efficacy-and-Safety-of-Venetoclax
4. FILO study: Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival.
https://ash.confex.com/ash/2023/webprogram/Paper185437.html
5. AUGMENT-101: Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results
https://ash.confex.com/ash/2023/webprogram/Paper172422.html
6. VEN+HMA in HR MDS: Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study
https://ash.confex.com/ash/2020/webprogram/Paper139492.html
-
In this episode, we talk about GVHD prophylaxis, including recent data on post-transplant cyclophosphamide and abatacept with Dr. Shernan Holtan from the University of Minnesota.
Here are the key trials we discussed:
1. BMT CTN 1203 trial: Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of GVHD in allogeneic transplantation.
https://pubmed.ncbi.nlm.nih.gov/30824040/
2. BMT CTN 1703 study: Post-Transplantation Cyclophosphamide-Based GVHD prophylaxis
https://pubmed.ncbi.nlm.nih.gov/37342922/
3. Patient-Reported Outcomes of BMT CTN 1703
https://ash.confex.com/ash/2023/webprogram/Paper187859.html
4. Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil
https://pubmed.ncbi.nlm.nih.gov/37311510/
5. BMT CTN 1301 trial: Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies
https://pubmed.ncbi.nlm.nih.gov/34855460/
6. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD (ABA2)
https://pubmed.ncbi.nlm.nih.gov/33449816/
7. Aurora Kinase a Inhibition for Gvhd and Relapse Prevention after Allogeneic HCT: Phase I Trial in Combination with Ptcy/Sirolimus
https://ash.confex.com/ash/2023/webprogram/Paper181292.html
-
In this episode, we discuss the key abstracts in myeloma and related plasma cell disorders at ASH23 with Dr. Benjamin Derman. Here are the abstracts discussed in this episode:
First, we will focus on a few abstracts in precursor states, MGUS.
1. New diagnostic criteria for light chain MGUS (IStopMM):
https://ash.confex.com/ash/2023/webprogram/Paper188547.html
https://ash.confex.com/ash/2023/webprogram/Paper182661.html
2. PERSEUS Trial-Dara-VRD vs VRD in newly diagnosed transplant-eligible myeloma:
https://ash.confex.com/ash/2023/webprogram/Paper191911.html
3. ISKIA trial: Isa-KRD vs KRD in newly diagnosed transplant-eligible myeloma:
https://ash.confex.com/ash/2023/webprogram/Paper177546.html
4. Phase 1/2 study for Daratumumab-Venetoclax-Dexamethasone in early relapsed t(11;14) myeloma:
https://ash.confex.com/ash/2023/webprogram/Paper180766.html
5. GMMG Relapse Trial (Long-term follow-up data from randomized controlled trial of salvage transplant in myeloma)
https://ash.confex.com/ash/2023/webprogram/Paper178835.html6. Overall survival results of KarMMa-3 trial
https://ash.confex.com/ash/2023/webprogram/Paper178933.html
7. GEM2017FIT Trial: Dara-KRd vs KRd vs VMP-RD in non-transplant eligible patients:
https://ash.confex.com/ash/2023/webprogram/Paper179866.html
-
In this episode, we review the hottest updates in lymphoma from the American Society of Hematology 2023 meeting with Dr Toby Eyre, a consultant haematologist at the University of Oxford in the UK.
Here are the abstracts that were discussed:
Mantle Cell Lymphoma
1. BOVen trial-A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Treatment-Naïve, TP53-Mutant Mantle Cell Lymphoma
https://ash.confex.com/ash/2023/webprogram/Paper180069.html
2. SYMPATICO Trial: Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma (Late Breaking Abstract)
https://ash.confex.com/ash/2023/webprogram/Paper191921.html
Chronic Lymphocytic Leukemia
1. FLAIR trial: Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
Link for simultaneous NEJM publication: https://www.nejm.org/doi/10.1056/NEJMoa2310063
2. Ibrutinib retreatment in Phase 2 CAPTIVATE study:
https://ash.confex.com/ash/2023/webprogram/Paper187128.html
Hodgkin Lymphoma
1. S1826 outcomes in older adults:
https://ash.confex.com/ash/2023/webprogram/Paper180114.html
Diffuse Large B-cell Lymphoma
1. Smart STOP study: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma
https://ash.confex.com/ash/2023/webprogram/Paper180381.html
2. Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
https://ash.confex.com/ash/2023/webprogram/Paper177588.html
-
In this episode, we delve into the weeds of bispecific antibodies across lymphomas with Dr. Michael Dickinson from Peter MacCallum Cancer Center, Melbourne, Australia. Here are the key articles we discussed:
1. Glofitamab for Relapsed/Refractory DLBCL:
https://pubmed.ncbi.nlm.nih.gov/36507690/
2. Long-term follow-up data on blinatumomab in relapsed/refractory B-cell NHL:
https://pubmed.ncbi.nlm.nih.gov/31451445/
3. Phase 1/2 study of epcoritamab in relapsed/refractory DLBCL:
https://pubmed.ncbi.nlm.nih.gov/36548927/
4. Phase 2 trial of mosunetuzumab in relapsed/refractory follicular lymphoma:
https://pubmed.ncbi.nlm.nih.gov/35803286/
5. Phase 1 trial of odronextamab in relapsed/refractory B-cell NHL:
https://pubmed.ncbi.nlm.nih.gov/35366963/
6. Epcoritamab + R2 in high-risk follicular lymphoma:
https://meetings.asco.org/abstracts-presentations/218265
7. Glofitamab in Mantle Cell Lymphoma:
https://ashpublications.org/blood/article/140/Supplement%201/178/489039
-
In this episode, we dive into the management of newly diagnosed and relapsed FLT3-positive AML with Dr. Alexander Perl.
Here are the shownotes:
1. Assessment of minimal residual disease in standard-risk AMLhttps://www.nejm.org/doi/full/10.1056/nejmoa1507471
2. RATIFY study: Midostaurin plus chemotherapy for AML with a FLT3 mutation
https://www.nejm.org/doi/full/10.1056/nejmoa1614359
3. QuANTUM-First trial: Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00464-6/fulltext
4. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups
https://ashpublications.org/blood/article/127/12/1551/35035/Benefit-of-high-dose-daunorubicin-in-AML-induction
5. Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia
https://ascopubs.org/doi/10.1200/JCO.2017.72.8618?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
6. Phase 3 trial of gilteritinib plus azacitidine vs. azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy
https://ashpublications.org/blood/article/140/17/1845/486088/Phase-3-trial-of-gilteritinib-plus-azacitidine-vs
7. ADMIRAL: Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
https://www.nejm.org/doi/full/10.1056/nejmoa1902688
8. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
https://ascopubs.org/doi/10.1200/JCO.22.00602?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
9. Levis MJ, Hamadani M, Logan B, et al: BMT-CTN 1506 (MORPHO): A randomized trial of the FLT3 inhibitor gilteritinib as post-transplant maintenance for FLT3-ITD AML. EHA 2023 Hybrid Congress. Abstract LB2711. Presented June 11, 2023.
10. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30455-1/fulltext?dgcid=raven_jbs_etoc_email
- Laat meer zien
